Study Phase 3, randomized, double-blind, placebo, multicenter controlled to evaluate the effectiveness and safety of Alxn1850 (recombinant alkaline phosphatase) administered via subcutaneous participants (12 to
Casa dos Rare informs: Strong> We use cookies to customize ads and improve your experience on the site. By continuing, you agree with our Política de Privacidade.
continue and close